CD8A and neoplasm: They found that IT delivery of these OV as monotherapies resulted in transient tumor regressions followed by gradual tumor progression in most mice; but, when VT1093M and VT1092M were co-injected IT, durable tumor regressions were observed in all mice, accompanied by the largest increase in tumor-infiltrating CD4+ and CD8+ T cells and overall survival rates.